FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3167291264> ?p ?o ?g. }

• W3167291264 abstract "Glioblastoma (GBM) is the most common malignant primary brain tumor, accounting for ~57% of all gliomas and 48% of all malignant primary central nervous system tumors in the United States. Abnormal expression of the replication factor C subunit 2 (RFC2) gene and microRNA (miR)‑744‑5p is associated with tumorigenic characteristics, including cellular proliferation, migration and invasiveness. However, the mechanism underlying the interaction between miR‑744‑5p and RFC2 in GBM remains unknown. Reverse transcription‑quantitative (RT‑q) PCR analysis of RFC2 and miR‑744‑5p was performed using GBM tumor tissues and cells, and the association between miR‑744‑5p and RFC2 was determined by dual‑luciferase reporter assay. Cell Counting Kit 8, 5‑bromo‑2‑deoxyuridine (BrdU), wound‑healing and cellular adhesion assays, as well as the detection of caspase‑3 activity and western blotting were used to detect cellular proliferation, migration and adhesion, caspase‑3 activity, and Bax and Bcl‑2 protein expression, respectively, in GBM cells. The results of the present study demonstrated that RFC2 expression was increased in GBM tissues and cell lines. Overexpression of RFC2 promoted cellular proliferation, migration, adhesion and an increase in Bcl‑2 protein levels, and suppressed cellular caspase‑3 activity and Bax protein expression, while silencing RFC2 resulted in the opposite effect. The effects of miR‑744‑5p inhibition were similar to those of RFC2 overexpression. Moreover, miR‑744‑5p was found to target RFC2 in GBM cells, and inhibiting the expression of RFC2 suppressed GBM tumorigenesis. In conclusion, the present study demonstrated that miR‑744‑5p targets RFC2 and suppresses the progression of GBM by repressing cellular proliferation, migration and Bcl‑2 protein expression, and effectively promoting caspase‑3 activity and Bax protein expression. These findings suggest a new target for the clinical treatment and improved prognosis of patients with GBM in the future." @default.
• W3167291264 created "2021-06-22" @default.
• W3167291264 creator A5005709794 @default.
• W3167291264 creator A5024123949 @default.
• W3167291264 creator A5053253686 @default.
• W3167291264 creator A5054075262 @default.
• W3167291264 creator A5075464087 @default.
• W3167291264 date "2021-06-15" @default.
• W3167291264 modified "2023-10-16" @default.
• W3167291264 title "MicroRNA‑744‑5p inhibits glioblastoma malignancy by suppressing replication factor C subunit 2" @default.
• W3167291264 cites W1879243586 @default.
• W3167291264 cites W2020812892 @default.
• W3167291264 cites W2023985769 @default.
• W3167291264 cites W2026064767 @default.
• W3167291264 cites W2036044314 @default.
• W3167291264 cites W2054717287 @default.
• W3167291264 cites W2077475358 @default.
• W3167291264 cites W2084605009 @default.
• W3167291264 cites W2106825272 @default.
• W3167291264 cites W2107277218 @default.
• W3167291264 cites W2109557450 @default.
• W3167291264 cites W2110700617 @default.
• W3167291264 cites W2122185352 @default.
• W3167291264 cites W2125466620 @default.
• W3167291264 cites W2134807618 @default.
• W3167291264 cites W2135947790 @default.
• W3167291264 cites W2146369211 @default.
• W3167291264 cites W2162674813 @default.
• W3167291264 cites W2265419075 @default.
• W3167291264 cites W2343662962 @default.
• W3167291264 cites W2443120933 @default.
• W3167291264 cites W2552834147 @default.
• W3167291264 cites W2760439765 @default.
• W3167291264 cites W2770409448 @default.
• W3167291264 cites W2807555908 @default.
• W3167291264 cites W2898575402 @default.
• W3167291264 cites W2899074378 @default.
• W3167291264 cites W2954277215 @default.
• W3167291264 cites W2960131742 @default.
• W3167291264 cites W2974402721 @default.
• W3167291264 cites W2979082643 @default.
• W3167291264 cites W2994900430 @default.
• W3167291264 cites W3014748532 @default.
• W3167291264 cites W3014861873 @default.
• W3167291264 cites W3025869976 @default.
• W3167291264 cites W3032984940 @default.
• W3167291264 cites W4234865248 @default.
• W3167291264 doi "https://doi.org/10.3892/ol.2021.12869" @default.
• W3167291264 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8227640" @default.
• W3167291264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34188710" @default.
• W3167291264 hasPublicationYear "2021" @default.
• W3167291264 type Work @default.
• W3167291264 sameAs 3167291264 @default.
• W3167291264 citedByCount "2" @default.
• W3167291264 countsByYear W31672912642022 @default.
• W3167291264 crossrefType "journal-article" @default.
• W3167291264 hasAuthorship W3167291264A5005709794 @default.
• W3167291264 hasAuthorship W3167291264A5024123949 @default.
• W3167291264 hasAuthorship W3167291264A5053253686 @default.
• W3167291264 hasAuthorship W3167291264A5054075262 @default.
• W3167291264 hasAuthorship W3167291264A5075464087 @default.
• W3167291264 hasBestOaLocation W31672912641 @default.
• W3167291264 hasConcept C104317684 @default.
• W3167291264 hasConcept C119056186 @default.
• W3167291264 hasConcept C121608353 @default.
• W3167291264 hasConcept C145059251 @default.
• W3167291264 hasConcept C153911025 @default.
• W3167291264 hasConcept C190283241 @default.
• W3167291264 hasConcept C2778227246 @default.
• W3167291264 hasConcept C2781018059 @default.
• W3167291264 hasConcept C29537977 @default.
• W3167291264 hasConcept C502942594 @default.
• W3167291264 hasConcept C54355233 @default.
• W3167291264 hasConcept C55493867 @default.
• W3167291264 hasConcept C555283112 @default.
• W3167291264 hasConcept C62112901 @default.
• W3167291264 hasConcept C86803240 @default.
• W3167291264 hasConceptScore W3167291264C104317684 @default.
• W3167291264 hasConceptScore W3167291264C119056186 @default.
• W3167291264 hasConceptScore W3167291264C121608353 @default.
• W3167291264 hasConceptScore W3167291264C145059251 @default.
• W3167291264 hasConceptScore W3167291264C153911025 @default.
• W3167291264 hasConceptScore W3167291264C190283241 @default.
• W3167291264 hasConceptScore W3167291264C2778227246 @default.
• W3167291264 hasConceptScore W3167291264C2781018059 @default.
• W3167291264 hasConceptScore W3167291264C29537977 @default.
• W3167291264 hasConceptScore W3167291264C502942594 @default.
• W3167291264 hasConceptScore W3167291264C54355233 @default.
• W3167291264 hasConceptScore W3167291264C55493867 @default.
• W3167291264 hasConceptScore W3167291264C555283112 @default.
• W3167291264 hasConceptScore W3167291264C62112901 @default.
• W3167291264 hasConceptScore W3167291264C86803240 @default.
• W3167291264 hasIssue "2" @default.
• W3167291264 hasLocation W31672912641 @default.
• W3167291264 hasLocation W31672912642 @default.
• W3167291264 hasOpenAccess W3167291264 @default.
• W3167291264 hasPrimaryLocation W31672912641 @default.
• W3167291264 hasRelatedWork W1998561093 @default.
• W3167291264 hasRelatedWork W2103211592 @default.
• W3167291264 hasRelatedWork W2117441185 @default.

• next